Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Lee

Showing results (511-520 of 594) with videos related to

Pageof 60
Sort By:
Journal of the National Cancer Institute|January 17, 2012
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomeNathan T Ihle, Lauren A Byers, Edward S Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLCXiuning Le, Sonam Puri, Marcelo V Negrao, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 12, 2018
AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public HealthScott M Lippman, Cory Abate-Shen, Karen L Colbert Maresso, et al.
Science (New York, N.Y.)|October 11, 2014
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencingJianjun Zhang, Junya Fujimoto, Jianhua Zhang, et al.
Oncotarget|October 20, 2018
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i>-altered non-small cell lung cancerDennis Ruder, Vassiliki Papadimitrakopoulou, Kazuhiko Shien, et al.
Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.
JTO Clinical and Research Reports|August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLCKaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
Medrxiv : the Preprint Server for Health Sciences|March 17, 2025
KRAS <sup>G12D</sup> -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC PatientsValerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan, et al.
JAMA Oncology|March 23, 2023
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical TrialDavide Serrano, Sara Gandini, Parjhitham Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Pageof 60

Showing results (511-520 of 594) with videos related to

Sort By:
Pageof 60
Journal of the National Cancer Institute|January 17, 2012
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomeNathan T Ihle, Lauren A Byers, Edward S Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLCXiuning Le, Sonam Puri, Marcelo V Negrao, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 12, 2018
AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public HealthScott M Lippman, Cory Abate-Shen, Karen L Colbert Maresso, et al.
Science (New York, N.Y.)|October 11, 2014
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencingJianjun Zhang, Junya Fujimoto, Jianhua Zhang, et al.
Oncotarget|October 20, 2018
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i>-altered non-small cell lung cancerDennis Ruder, Vassiliki Papadimitrakopoulou, Kazuhiko Shien, et al.
Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.
JTO Clinical and Research Reports|August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLCKaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
Medrxiv : the Preprint Server for Health Sciences|March 17, 2025
KRAS <sup>G12D</sup> -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC PatientsValerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan, et al.
JAMA Oncology|March 23, 2023
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical TrialDavide Serrano, Sara Gandini, Parjhitham Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Pageof 60